About Us
Biosimax Lifesciences, a new UK company, supported by partners will develop and bring to market, high quality, life-changing biosimilars medicines using the UK’s unique lifesciences and healthcare capabilities.
Through a unique and innovative business model, Biosimax Lifesciences will create:
A New Pathway
Providing biosimilar products pioneered within the UK healthcare system
UK Supply Chain
Robust supply of critical biological medicines from the United Kingdom
Reduced Costs
Significant cost savings, enabling wider access to quality medicines
Highly Profitable
Quickly cash-accretive, low risk and reproducible commercial business
Meet the Biosimax Team
We have a breadth of specialist skills and experience
The Biosimax team has decades of experience in the pharmaceutical industry and strong link to academia, the NHS and the MHRA.
Adrian Wallis
Chief Executive Officer
Pat McIver
Chief Operating Officer
Tim Cooper
Chief Financial Officer
Dr Theodore Willison-Parry
Chief Medical Officer
Professor Clive Badman
Director
Professor Luigi Martini
Director